{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:47:47Z","timestamp":1762876067900,"version":"3.37.3"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BO 3815\/4-1"],"award-info":[{"award-number":["BO 3815\/4-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KfH Stiftung Pr\u00e4ventivmedizin e.V."},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ER1206; 01ER1507"],"award-info":[{"award-number":["01ER1206; 01ER1507"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0213157","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T17:34:54Z","timestamp":1553189694000},"page":"e0213157","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIAbetes COhoRtE (DIACORE) study"],"prefix":"10.1371","volume":"14","author":[{"given":"Myriam","family":"Rheinberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Segiet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Nusser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnther","family":"Kreisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Andreae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Manz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Banas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Stark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Lammert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Gorski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris M.","family":"Heid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard K.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten A.","family":"B\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"S Wild","year":"2004","journal-title":"Diabetes care"},{"year":"2013","key":"ref2"},{"issue":"9","key":"ref3","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.2337\/dc11-0175","article-title":"Observation on renal outcomes in the Veterans Affairs Diabetes Trial","volume":"34","author":"L Agrawal","year":"2011","journal-title":"Diabetes care"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/j.1523-1755.2005.00227.x","article-title":"Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991\u20132000).","volume":"67","author":"PC Van Dijk","year":"2005","journal-title":"Kidney international"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1093\/ndt\/gfg288","article-title":"The importance of diabetic nephropathy in current nephrological practice.","volume":"18","author":"F Locatelli","year":"2003","journal-title":"Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association\u2014European Renal Association"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"653789","DOI":"10.1155\/2013\/653789","article-title":"Impact of diabetes on cardiovascular disease: an update","volume":"2013","author":"AS Matheus","year":"2013","journal-title":"International journal of hypertension"},{"issue":"9131","key":"ref7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"7160","key":"ref8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","year":"1998","journal-title":"Bmj"},{"issue":"9131","key":"ref9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"24","key":"ref10","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"A Patel","year":"2008","journal-title":"The New England journal of medicine"},{"issue":"9590","key":"ref11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"A Patel","year":"2007","journal-title":"Lancet"},{"issue":"17","key":"ref12","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"WC Cushman","year":"2010","journal-title":"The New England journal of medicine"},{"key":"ref13","article-title":"Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes","author":"S Zoungas","year":"2014","journal-title":"The New England journal of medicine"},{"issue":"10","key":"ref14","first-page":"978","article-title":"Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes","volume":"373","author":"RA Hayward","year":"2015","journal-title":"The New England journal of medicine"},{"issue":"24","key":"ref15","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"HC Gerstein","year":"2008","journal-title":"The New England journal of medicine"},{"issue":"22","key":"ref16","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"B Zinman","year":"2015","journal-title":"The New England journal of medicine"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"H Haller","year":"2011","journal-title":"The New England journal of medicine"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"RR Wing","year":"2013","journal-title":"The New England journal of medicine"},{"issue":"14","key":"ref19","first-page":"704","article-title":"Diabetic nephropathy: new insights into diagnosis, prevention and treatment","volume":"139","author":"M Rheinberger","year":"2014","journal-title":"Dtsch Med Wochenschr"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0041-109591","article-title":"New aspects in prevention and therapy of diabetic nephropathy","volume":"141","author":"M Rheinberger","year":"2016","journal-title":"Dtsch Med Wochenschr"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2350-14-25","article-title":"Study design of DIACORE (DIAbetes COhoRtE)\u2014a cohort study of patients with diabetes mellitus type 2","volume":"14","author":"L Dorhofer","year":"2013","journal-title":"BMC Med Genet"},{"issue":"9","key":"ref22","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"AS Levey","year":"2009","journal-title":"Annals of internal medicine"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"LA Inker","year":"2012","journal-title":"The New England journal of medicine"},{"issue":"9854","key":"ref24","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"CS Fox","journal-title":"Lancet"},{"issue":"1","key":"ref25","first-page":"1","article-title":"Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"A Levin","year":"2013","journal-title":"Kidney International Supplements"},{"key":"ref26","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes\u2013Langfassung, 1. Auflage. Version 4. 2013. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.leitlinien.de\/mdb\/downloads\/nvl\/diabetes-mellitus\/dm-therapie-1aufl-vers4-lang.pdf\" xlink:type=\"simple\">https:\/\/www.leitlinien.de\/mdb\/downloads\/nvl\/diabetes-mellitus\/dm-therapie-1aufl-vers4-lang.pdf<\/ext-link>"},{"issue":"Supplement 1","key":"ref27","article-title":"Standards of Medical Care in Diabetes\u20142016","volume":"39","year":"2016","journal-title":"Diabetes care"},{"issue":"14","key":"ref28","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).","volume":"32","author":"Z Reiner","year":"2011","journal-title":"European heart journal"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"W Duckworth","year":"2009","journal-title":"The New England journal of medicine"},{"issue":"19","key":"ref30","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"SP Marso","year":"2016","journal-title":"The New England journal of medicine"},{"issue":"23","key":"ref31","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"HH Parving","year":"2012","journal-title":"The New England journal of medicine"},{"issue":"9","key":"ref32","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/dc12-1759","article-title":"Quality of care of people with type 2 diabetes in eight European countries: findings from the Guideline Adherence to Enhance Care (GUIDANCE) study","volume":"36","author":"MA Stone","year":"2013","journal-title":"Diabetes care"},{"issue":"7","key":"ref33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"B Neal","year":"2017","journal-title":"The New England journal of medicine"},{"issue":"4","key":"ref34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"C Wanner","year":"2016","journal-title":"The New England journal of medicine"},{"issue":"9","key":"ref35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and Renal Outcomes in Type 2 Diabetes","volume":"377","author":"JFE Mann","year":"2017","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"AI Adler","year":"2003","journal-title":"Kidney international"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0213157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:17:17Z","timestamp":1588965437000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0213157"}},"subtitle":[],"editor":[{"given":"Karin","family":"Jandeleit-Dahm","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0213157","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,3,21]]}}}